403 related articles for article (PubMed ID: 9691412)
1. [Therapy of terminal dilated cardiomyopathy with growth hormone].
Dreifuss P
Z Kardiol; 1998 Jun; 87(6):425-35. PubMed ID: 9691412
[TBL] [Abstract][Full Text] [Related]
2. [Dilated cardiomyopathy and growth hormone].
Dreifuss P
Z Kardiol; 2002 Dec; 91(12):973-7. PubMed ID: 12490987
[TBL] [Abstract][Full Text] [Related]
3. [Therapy of dilated cardiomyopathy with recombinant human growth hormone].
Osterziel KJ; Markus U; Willenbrock R; Strohm O; Dietz R
Z Kardiol; 1997 Oct; 86(10):803-11. PubMed ID: 9454447
[TBL] [Abstract][Full Text] [Related]
4. Role of growth hormone in chronic heart failure: therapeutic implications.
Volterrani M; Giustina A; Manelli F; Cicoira MA; Lorusso R; Giordano A
Ital Heart J; 2000 Nov; 1(11):732-8. PubMed ID: 11110515
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human growth hormone treatment for dilated cardiomyopathy in children.
McElhinney DB; Colan SD; Moran AM; Wypij D; Lin M; Majzoub JA; Crawford EC; Bartlett JM; McGrath EA; Newburger JW
Pediatrics; 2004 Oct; 114(4):e452-8. PubMed ID: 15466071
[TBL] [Abstract][Full Text] [Related]
6. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy.
Osterziel KJ; Strohm O; Schuler J; Friedrich M; Hänlein D; Willenbrock R; Anker SD; Poole-Wilson PA; Ranke MB; Dietz R
Lancet; 1998 Apr; 351(9111):1233-7. PubMed ID: 9643742
[TBL] [Abstract][Full Text] [Related]
7. Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management.
Castelli G; Fornaro A; Ciaccheri M; Dolara A; Troiani V; Tomberli B; Olivotto I; Gensini GF
Circ Heart Fail; 2013 Sep; 6(5):913-21. PubMed ID: 23888044
[TBL] [Abstract][Full Text] [Related]
8. The somatotrophic system in patients with dilated cardiomyopathy: relation of insulin-like growth factor-1 and its alterations during growth hormone therapy to cardiac function.
Osterziel KJ; Ranke MB; Strohm O; Dietz R
Clin Endocrinol (Oxf); 2000 Jul; 53(1):61-8. PubMed ID: 10931081
[TBL] [Abstract][Full Text] [Related]
9. Role of growth hormone in chronic heart failure. Therapeutic implications.
Volterrani M; Manelli F; Cicoira M; Lorusso R; Giustina A
Drugs; 2000 Oct; 60(4):711-9. PubMed ID: 11085197
[TBL] [Abstract][Full Text] [Related]
10. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy.
Fazio S; Sabatini D; Capaldo B; Vigorito C; Giordano A; Guida R; Pardo F; Biondi B; Saccà L
N Engl J Med; 1996 Mar; 334(13):809-14. PubMed ID: 8596546
[TBL] [Abstract][Full Text] [Related]
11. Progressive cardiac dysfunction and fibrosis in the cardiomyopathic hamster and effects of growth hormone and angiotensin-converting enzyme inhibition.
Ryoke T; Gu Y; Mao L; Hongo M; Clark RG; Peterson KL; Ross J
Circulation; 1999 Oct; 100(16):1734-43. PubMed ID: 10525494
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone treatment in dilated cardiomyopathy.
Perrot A; Ranke MB; Dietz R; Osterziel KJ
J Card Surg; 2001; 16(2):127-31. PubMed ID: 11766830
[TBL] [Abstract][Full Text] [Related]
13. Effects of simultaneous alterations in preload and afterload on measurements of left ventricular contractility in patients with dilated cardiomyopathy: comparisons of ejection phase, isovolumetric and end-systolic force-velocity indexes.
Borow KM; Neumann A; Marcus RH; Sareli P; Lang RM
J Am Coll Cardiol; 1992 Oct; 20(4):787-95. PubMed ID: 1527288
[TBL] [Abstract][Full Text] [Related]
14. [Therapy of dilated cardiomyopathy with digitalis, diuretics and vasodilators].
Liebau G
Herz; 1985 Jun; 10(3):138-42. PubMed ID: 2991095
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: one-year follow-up results of the randomized trial.
Wojnicz R; Nowak J; Szyguła-Jurkiewicz B; Wilczek K; Lekston A; Trzeciak P; Nowalany-Kozielska E; Zembala M; Wodniecki J; Poloński L
Am Heart J; 2006 Oct; 152(4):713.e1-7. PubMed ID: 16996844
[TBL] [Abstract][Full Text] [Related]
16. Left ventricular geometry, myocardial function and energetics of the dilated left ventricle. Influence of vasodilators and positive inotropic substances.
Holubarsch C; Hasenfuss G; Thierfelder L; Just H
Herz; 1991 Sep; 16 Spec No 1():298-303. PubMed ID: 1820296
[TBL] [Abstract][Full Text] [Related]
17. Administration of insulin-like growth factor-1 (IGF-1) improves both structure and function of delta-sarcoglycan deficient cardiac muscle in the hamster.
Serose A; Prudhon B; Salmon A; Doyennette MA; Fiszman MY; Fromes Y
Basic Res Cardiol; 2005 Mar; 100(2):161-70. PubMed ID: 15611844
[TBL] [Abstract][Full Text] [Related]
18. Is growth hormone good for the heart?
Silverman BL; Friedlander JR
J Pediatr; 1997 Jul; 131(1 Pt 2):S70-4. PubMed ID: 9255233
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic relevance of left ventricular diastolic function parameters in dilated cardiomyopathy].
Schannwell CM; Schoebel FC; Marx R; Plehn G; Leschke M; Strauer BE
Z Kardiol; 2001 Apr; 90(4):269-79. PubMed ID: 11381575
[TBL] [Abstract][Full Text] [Related]
20. [Growth hormone secretion in heart failure].
Giustina A; Bonadonna S; Burattin A; Manelli F; Lorusso R; Volterrani M; Villa S; Dei Cas L; Agabiti Rosei E
Minerva Endocrinol; 2003 Mar; 28(1):1-11. PubMed ID: 12621359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
